196695-49-5

Upstream product

• 196695-32-6 {(4-Benzyloxy-benzyl)-[(S)-2-benzyloxycarbonylamino-3-(1-trityl-1H-imidazol-4-yl)-propionyl]-amino}-acetic acid methyl ester 
• 196695-33-7 (S)-{(4-benzyloxy-benzyl)-[2-benzyloxycarbonylamino-3-(1-trityl-1H-imidazol-4-yl)-propionyl]-amino}-acetic acid 
• 175708-57-3 [(4-benzyloxy-benzyl)-amino]-acetic acid methyl ester 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 209907-10-8 [(S)-1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer

Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.

Cycloalkyl inhibitors of protein farnesyltransferase

Novel inhibitors of protein farnesyltransferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer, restenosis, atheros